no campo quebrava o contexto e executava script. */ var MODAL_VRAL_TITLE = "We're pleased you're enjoying ONdrugDelivery."; var MODAL_VRAL_CONTENT = "You've reached your article limit for this week. Subscribe FREE to gain unlimited access to all content, functionality and more!"; var MODAL_VRAL_PREMIUM = "You've reached your article limit for this week. Subscribe FREE to gain unlimited access to all content, functionality and more!";

advanced search

Insilico Medicine

Insilico Medicine is a biotech company powered by AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties.


Visit Website

Headquarters
Insilico Medicine, Inc
345 Park Avenue South
2nd Floor Suite 006
New York
NY 10010
United States

Phone / Contact

E: [email protected]

Connect

Insilico Medicine is a global clinical-stage biotechnology company powered by generative AI, connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases and ageing-related diseases.

The company was founded in 2014 by Alex Zhavoronkov and is privately owned.

Authors and Contacts

Brita Belli
Head of Public Relations
Insilico Medicine

Article

PHARMA INSIGHT
Brita Belli
DEVELOPING AN INHALABLE FORMULATION OF THE FIRST GENERATIVE AI DRUG
Brita Belli introduces Insilico Medecine’s inhalable formulation of its AI-designed therapy for the treatment of idiopathic pulmonary fibrosis, its progression through clinical trials and the company’s approach to generative AI in the pharmaceutical space more broadly.
Top